Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
about
Pharmacological treatment for memory disorder in multiple sclerosisGlatiramer acetate for multiple sclerosisPharmacologic treatment for memory disorder in multiple sclerosisCognitive impairment in multiple sclerosisTreatment of cognitive impairment in patients with multiple sclerosisImpact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational studyTherapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Cognitive changes in multiple sclerosis.BDNF+/- mice exhibit deficits in oligodendrocyte lineage cells of the basal forebrain.Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.Assessment and rehabilitation of cognitive impairment in multiple sclerosis.Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Treatment of cognitive impairment in multiple sclerosis: position paper.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.Evaluating response to disease-modifying therapy in relapsing multiple sclerosis.Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.Immunomodulatory treatments and cognition in MS.Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery.Capacity for financial decision making in multiple sclerosis.Relationship between global cognitive decline and depressive symptoms in multiple sclerosis.Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.Social cognition and Theory of Mind in patients with relapsing-remitting multiple sclerosis.The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.Memory decline evolves independently of disease activity in MS.Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients.Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.
P2860
Q24201735-1D1DED9D-39E4-421B-99B2-9F114A79CF19Q24235498-72752E92-2358-47E6-8736-55F76A722E28Q24236019-82E8EA6C-DE8E-4CC0-8CBF-46EA6930E10FQ28270988-569F7163-F119-453B-938A-6F12F51B01B8Q28272736-94BA6BA8-A544-443E-B7AD-FEE4AC344F2BQ28730321-A31849E8-9902-49C2-BECA-323F5C904F87Q30869048-04F4C122-99BC-402A-BCC4-F36E6FE58A92Q33377548-FE67F233-30C8-4166-A555-084E41D43058Q33778096-5EE35205-CFAB-4FC9-98FB-9C65697EDCEEQ36613378-728A5663-4EFE-4A6C-8CBB-18B6A9DFFCC3Q37707371-94111848-A603-4A98-B461-57ED8068543DQ37710114-E4CB8FF7-7CE8-484E-9A72-A000CBA98F52Q37736791-1097EA1F-A219-414E-81B2-8F57FA886B14Q37976344-50E72BF2-613F-4E47-9AD2-86CE2BA02F58Q38062466-8C378043-820D-4846-9834-6CDEE0DC913CQ38152977-2E196575-C1BF-4A31-A52E-6A7CAE2D8AF9Q38375605-79C5F157-87EB-49A5-BE83-E88E0D6DC69BQ38736551-81627070-F936-402F-9BCF-A68FD268A8EAQ38942635-1755B3E2-7C89-47C4-A93B-93D18972CAAFQ47935971-D444A556-082B-447F-8954-F1FD3EAE2527Q47979850-819BA9DD-AFFF-4ADF-9290-5DF56C0D273BQ48707110-569E477B-BF5A-4674-A50E-97E8BEF697BCQ49041541-AE1648BE-3760-428F-97A5-292475F997CCQ50720208-12F954CF-CBAE-47CC-A576-9DA34D4CA32EQ51036113-6D44CA89-9D5C-42AD-8E22-26494B7421F6Q51963829-067D57C8-58DE-40CC-858E-73CB62C8850EQ52091201-5AAE5D87-1F06-483F-AA86-E9DAE921CA5CQ53379362-8DB63700-3B04-4BAC-BF9D-AABA0F7F69C5
P2860
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cognitive function in relapsin ...... s in a 10-year clinical trial.
@en
type
label
Cognitive function in relapsin ...... s in a 10-year clinical trial.
@en
prefLabel
Cognitive function in relapsin ...... s in a 10-year clinical trial.
@en
P2093
P1476
Cognitive function in relapsin ...... s in a 10-year clinical trial.
@en
P2093
Amy Weinstein
Andrew D Goodman
Copaxone Study Group
Kenneth P Johnson
Michael P McDermott
Steven R Schwid
P356
10.1016/J.JNS.2007.01.070
P577
2007-02-28T00:00:00Z